Calcipotriol/betamethasone dipropionate ointment in mild-to-moderate paediatric psoriasis: long-term daily clinical practice data in a prospective cohort
| Autor: | M. van Geel, E.M.G.J. de Jong, Karlien Mul, P.C.M. van de Kerkhof, A.M. Oostveen, Marieke M B Seyger |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Male
medicine.medical_specialty Adolescent Betamethasone dipropionate Dermatology Betamethasone Ointments chemistry.chemical_compound Quality of life Calcitriol Psoriasis Area and Severity Index Psoriasis Medicine Humans Prospective Studies Prospective cohort study Child Calcipotriol Body surface area business.industry Dermatology Life Quality Index medicine.disease Disorders of movement Donders Center for Medical Neuroscience [Radboudumc 3] Drug Combinations Treatment Outcome chemistry Child Preschool Quality of Life Inflammatory diseases Radboud Institute for Health Sciences [Radboudumc 5] Female Dermatologic Agents business medicine.drug |
| Zdroj: | British Journal of Dermatology, 171, 2, pp. 363-9 British Journal of Dermatology, 171, 363-9 |
| ISSN: | 0007-0963 |
| Popis: | Contains fulltext : 138571.pdf (Publisher’s version ) (Closed access) BACKGROUND: Psoriasis in children has a significant negative impact on the quality of life (QoL) and effective treatment can improve this. The two-compound ointment calcipotriol 50 mug g(-1) and betamethasone dipropionate 0.5 mg g(-1) is an effective treatment option for moderate-to-severe psoriasis in adults. OBJECTIVES: To study prospectively the effectiveness and safety of calcipotriol/betamethasone dipropionate ointment in paediatric patients with mild-to-moderate plaque psoriasis in daily clinical practice and to investigate the influence on QoL. METHODS: Data were obtained from a prospective, longitudinal paediatric psoriasis registry, called Child-CAPTURE. Severity was assessed using the Psoriasis Area and Severity Index (PASI) and body surface area (BSA). The Children's Dermatology Life Quality Index (CDLQI) was used to assess QoL and visual analogue scores (VAS) for pain and itch were collected. For safety data the number of (serious) adverse events was recorded. RESULTS: Seventy-three patients (mean age 10.8 years, range 3-18) were treated for a median time of 35.0 weeks (range 1.0-176.0). At week 12, mean PASI decreased 15.4% (from 5.2 to 4.4), BSA barely changed, and median CDLQI decreased significantly from 5.5 to 4.0. VAS scores for pain and itch declined. At week 24, mean PASI decreased to 4.3 (17.3%). No related serious adverse events were observed. CONCLUSIONS: In this daily clinical practice study in paediatric psoriasis, calcipotriol/betamethasone dipropionate ointment initially improved mild-to-moderate psoriasis and then maintained its effect. In addition, it improved QoL, with few adverse events. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text